Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STREAMS: Autologous MSCs in Active Multiple Sclerosis
NCT01606215Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jan 2013
- Primary completion
- Aug 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cells in multiple sclerosis (MS) (2 arms), sponsored by Imperial College London. Primary endpoints: Number of Adverse Events Assessed by CTCAE v4.0 at 24 weeks and Number of GELs Newly Appearing at 24 weeks. Started Jan 2013; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01606215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01606215.